Table 1.
Patient characteristics and comparison between responders and non-responders to mogamulizumab. The p-value obtained using Khi-square or Fisher exact test for qualitative variables and using Student’s t-test or Mann–Whitney U test for quantitative variables, according to their distribution.
| Basic Features | Population (n = 21) |
Responders (n = 13) | Non-Responders (n = 8) |
p-Value |
|---|---|---|---|---|
| Sex (n, %) | 0.067 | |||
| Male | 12 (57.1) | 5 (38.5) | 7 (87.5) | - |
| Female | 9 (42.9) | 8 (61.5) | 1 (12.5) | - |
| Age (moy ± δ) | 68.0 ± 10.7 | 70.0 ± 11.9 | 64.8 ± 7.9 | 0.286 |
| Smoker (n, %) (n = 18 [12/6]) | 4 (22.2) | 2 (16.7) | 2 (33.3) | 0.569 |
| Alcohol consumption (n, %) (n = 18 [12/6]) | 4 (22.2) | 2 (16.7) | 2 (33.3) | 0.569 |
| Lymphoma type (n, %) | ||||
| Sézary | 16 (76.2) | 10 (76.9) | 6 (75.0) | 1.000 |
| Mycosis fungoïde | 5 (23.8) | 3 (23.1) | 2 (25.0) | |
| Delay from diagnosis to mogamulizumab introduction (in months) [median, Q1–Q3] | 32.0 [22.0–87.0] | 25.0 [15.0–87.0] | 44.5 [33.5–107.0] | 0.169 |
| T4-stage at mogamulizumab introduction (n, %) | 12 (57.1) | 7 (53.9) | 5 (62.5) | 1.000 |
| ECOG status at mogamulizumab introduction (n, %) | 0.194 | |||
| 0 | 10 (47.6) | 5 (38.5) | 5 (62.5) | 0.387 |
| 1 | 6 (28.6) | 4 (30.8) | 2 (25.0) | 1.000 |
| 2 | 4 (19.1) | 4 (30.8) | 0 (0.0) | 0.131 |
| 3 | 1 (4.8) | 0 (0.0) | 1 (12.5) | - |
| LDH level at mogamulizumab introduction (UI/L) [median, Q1–Q3] (n = 17 [10/7]) | 299.0 [211.0–365.0] | 260.0 [202.0–358.0] | 310.0 [211.0–379.0] | 0.591 |
| LDH level superior to 245 UI/L at mogamulizumab introduction (n, %) (n = 18 [10/8]) | 10 (55.6) | 5 (50.0) | 5 (62.5) | 0.664 |
| Number of Sézary cells at mogamulizumab introduction (g/L) [median, Q1–Q3] (n = 20 [12/8]) | 0.88 [0.02–6.66] | 2.85 [0.20–9.50] | 0.39 [0.003–3.15] | 0.296 |
| CD4/CD8 ratio before mogamulizumab introduction [median, Q1–Q3] (n = 17 [11/6]) | 9.6 [3.3–88.0] | 9.6 [3.0–89.0] | 8.4 [3.3–40.0] | 0.580 |
| CD4/CD8 ratio >10 before mogamulizumab introduction (n, %) (n = 17 [11/6]) | 7 (41.2) | 5 (45.5) | 2 (33.3) | 1.000 |
| Number of therapeutic lines [median, Q1–Q3] | 4.0 [3.0–5.0] | 3.0 [3.0–5.0] | 5.0 [4.5–6.0] | 0.070 |
| Patch type cutaneous before introduction of mogamulizumab (n, %) | 8 (38.1) | 6 (46.2) | 2 (25.0) | 0.400 |
| Plaque type cutaneous lesions (infiltrated) before introduction of mogamulizumab (n, %) | 7 (33.3) | 5 (38.5) | 2 (25.0) | 0.656 |
| Tumor type cutaneous lesions before introduction of mogamulizumab (n, %) | 2 (9.5) | 1 (7.7) | 1 (12.5) | 1.000 |
| Presence of any adenopathy before introduction of mogamulizumab (n, %) | 12 (57.1) | 7 (53.9) | 5 (62.5) | 1.000 |
| Cutaneous area affected before introduction of mogamulizumab (n, %) | 0.110 | |||
| 0% | 1 (4.8) | 0 (0.0) | 1 (12.5) | 0.381 |
| <10% | 2 (9.5) | 2 (15.4) | 0 (0.0) | 0.505 |
| 10–50% | 1 (4.8) | 0 (0.0) | 1 (12.5) | 0.381 |
| 5–80% | 4 (19.1) | 4 (30.8) | 0 (0.0) | 0.131 |
| >80% | 13 (61.9) | 7 (53.9) | 6 (75.0) | 0.400 |